Ares Management – a leading global alternative investment manager – announced that Ares Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI, a technology company leading the adoption of AI to advance precision medicine and patient care.
The financing is expected to support Tempus’ previously announced acquisition of Ambry Genetics, which closed on February 3, 2025. And combined with $260 million of capital provided in 2022 and 2023, And Ares Credit funds have provided Tempus a total debt package of about $560 million.
Launched in 2015, Tempus brings data and AI to healthcare businesses through innovative technology solutions focused on clinical care and…
